DataBase of pulmoNary hyPertesion in PoLish Population - BNP-PL
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age3+
SponsorPolish Cardiology Association
About this trial
The BNP-PL is a multicenter, observational study in which patients are prospectively followed in order to investigate clinical course and management of pulmonary hypertension in Poland.
All patients diagnosed with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension confirmed in right heart catheterization, will be eligible to participate in the study.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
are aged > 3 months at the time of enrollment
fulfill the following hemodinamic criteria: mean pulmonary arterial pressure (mPAP) of 25 mm Hg or more, mean pulmonary arterial wedge pressure (PAWP) or left ventricular end-diastolic pressure (PVEDP) of 15 mm Hg or less, pulmonary vascular resistance (PVR) of 3 Woods.
are aged > 3 months at the time of enrollment
fulfill the following hemodinamic criteria: mean pulmonary arterial pressure (mPAP) of 25 mm Hg or more, mean pulmonary arterial wedge pressure (PAWP) or left ventricular end-diastolic pressure (PVEDP) of 15 mm Hg or less, pulmonary vascular resistance (PVR) of 3 Woods
Disqualifiers
None
Trial population
Patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension treated in Polish centres of pulmonary hypertension accredited by the National Health Fund
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
3,000 Participants
are grouped into 3 trial groupsGroup A: PAH adults
Group B: PAH children
Group C: CTEPH
Trial outcomes
Primary outcomes
1
Mortality
The number of patients who die during the follow-up period
Time frame
Since enrollment until at least 5 years.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Polish Cardiology Association
Lead sponsor
Jagiellonian University
Collaborator
Source ClinicalTrials.gov